ANGLE PLC (LON:AGL) said the results of a new study from the University of Southern California (USC), published in the International Journal of Molecular Sciences, have highlighted the “key advantages” of its Parsortix liquid biopsy system compared to a standard of care tissue biopsy.
The AIM-listed firm said in addition to the known advantages of a non-invasive, repeatable and low cost procedure, the USC study showed that “potential actionable therapeutic targets” were found in the Parsortix biopsy that were missed in the tissue biopsy of a single metastatic site.
The study investigated concordance between cancer cells obtained from the blood test (circulating tumour cells - CTCs - harvested by Parsortix) and those obtained from the metastatic tissue biopsy across 4,600 medically relevant genes.
ANGLE said the study demonstrated “key capabilities of Parsortix for metastatic breast cancer”, the focus of its submission to the US Food and Drug Administration (FDA) which is planned for the third quarter of 2020.
"This study highlights both practical advantages of the Parsortix liquid biopsy in allowing non-invasive repeat biopsies in metastatic breast cancer and technical advantages in identifying actionable therapeutic targets that may be missed when relying on a single site tissue biopsy", Julie Lang, associate professor at USC’s Keck School of Medicine said in a statement.
ANGLE’s founder and chief executive Andrew Newland added: "The demonstration of advanced gene expression analysis techniques on CTCs harvested by Parsortix highlights an important potential clinical use of the Parsortix system once FDA clearance for metastatic breast cancer has been secured."
ANGLE shares rose 1.6% to 56.9p in early deals on Monday.